Drug Profile
BVT 115959
Alternative Names: BVT.115959; CBT-1008Latest Information Update: 24 Feb 2010
Price :
$50
*
At a glance
- Originator Cambridge Biotechnology
- Developer Swedish Orphan Biovitrum
- Class Analgesics
- Mechanism of Action Adenosine A2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammatory pain; Neuropathic pain